GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Chordate Medical Holding AB (OSTO:CMH) » Definitions » Retained Earnings

Chordate Medical Holding AB (OSTO:CMH) Retained Earnings : kr0.00 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Chordate Medical Holding AB Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Chordate Medical Holding AB's retained earnings for the quarter that ended in Dec. 2023 was kr0.00 Mil.

Chordate Medical Holding AB's quarterly retained earnings declined from Jun. 2023 (kr-14.41 Mil) to Sep. 2023 (kr-19.34 Mil) but then increased from Sep. 2023 (kr-19.34 Mil) to Dec. 2023 (kr0.00 Mil).


Chordate Medical Holding AB Retained Earnings Historical Data

The historical data trend for Chordate Medical Holding AB's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chordate Medical Holding AB Retained Earnings Chart

Chordate Medical Holding AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only - - - - -

Chordate Medical Holding AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -7.11 -14.41 -19.34 -

Chordate Medical Holding AB Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Chordate Medical Holding AB  (OSTO:CMH) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Chordate Medical Holding AB (OSTO:CMH) Business Description

Traded in Other Exchanges
Address
c/o Regus, Kistagangen 20B, Kista, SWE, 164 40
Chordate Medical Holding AB is a medical technology company that has developed and patented and CE-marked a new nerve-modulating treatment technology for chronic nasal congestion and chronic migraine. The company sells its products in Selected European markets, Israel and Saudi Arabia. The company's product range is based on the CE-marked treatment units Chordate System S100 and S120 for rhinitis and S220 for migraine, registered for the indications of preventive treatment of chronic migraine and chronic rhinitis and use on patients who are 18 years old or older. The company sells its product system, including treatments, through distributors to clinics and hospitals in its primary markets.

Chordate Medical Holding AB (OSTO:CMH) Headlines

No Headlines